RxSight announced the commercial launch of its newest Light Adjustable Lens, the LAL+. The company now offers two lenses in the Light Adjustable Lens platform: the LAL and the Light Adjustable Lens+, LAL+ . The LAL+ has a modified aspheric anterior surface that creates a small continuous increase in central lens power, which is designed to slightly extend the depth of focus. In addition, RxSight’s Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens , RxSight Light Delivery Device and accessories, will be the subject of various doctor presentations at the annual meeting of the American Society of Cataract and Refractive Surgery,ASCRS, in Boston on April 5-8.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXST:
- RxSight Announces Commercial Launch of its Newest Light Adjustable Lens™, the LAL+™, and Features Multiple Doctor Presentations at the Upcoming ASCRS Annual Meeting
- RxSight, Inc. to Participate in the 23rd Annual Needham Virtual Healthcare Conference
- RxSight price target raised to $65 from $36 at Morgan Stanley
- RxSight, Inc. to Participate in the 34th Annual Oppenheimer Healthcare Conference
- RxSight price target raised to $64 from $54 at Stifel
